Esperion Therapeutics ESPR Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's total current liabilities?
- Esperion Therapeutics (ESPR) reported total current liabilities of $300.36M in Q1 2026.
- How has Esperion Therapeutics's total current liabilities changed year-over-year?
- Esperion Therapeutics's total current liabilities increased by 10.8% year-over-year, from $270.97M to $300.36M.
- What is the long-term trend for Esperion Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Esperion Therapeutics's total current liabilities has grown at a 26.2% compound annual growth rate (CAGR), from $94.07M to $300.81M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.